Bayer Wins St. Louis Roundup Trial as Settlement Faces Review

By EC Assets · Published 30 October 2026

Bayer AG secured a defense verdict in a Missouri courtroom after a jury rejected allegations that its Roundup weedkiller causes cancer. The decision in St. Louis dismissed claims brought by three cancer patients against the German agrochemical company. The outcome bolsters Bayer's ongoing push to contain the legal costs linked to tens of thousands of similar lawsuits. Bayer shares rose 4.19 percent following the decision. The litigation in St. Louis centered on claims from three women who blamed Roundup for their cancer diagnoses. During the trial, attorneys representing the plaintiffs told the Missouri jury that Bayer's Monsanto unit failed to adequately test the weedkiller before selling it to the public. Jurors rejected those arguments and cleared the company of liability. The verdict marks Bayer's first Roundup trial victory since a significant ruling by the U.S. Supreme Court. The Supreme Court previously ruled on a Thursday that Bayer may not be sued over the absence of cancer warning labels on the packaging of Roundup weedkiller. The Missouri proceeding acted as an initial trial test for remaining Roundup claims following that Supreme Court determination. In parallel with courtroom defenses, Bayer's Monsanto unit is awaiting a critical judicial decision on a comprehensive class agreement. On Monday, September 14, Monsanto urged a Missouri judge to approve a proposed $7.25 billion settlement. That proposed agreement is designed to resolve widespread lawsuits alleging that the weedkiller causes cancer. The trial victory in St. Louis provides support for Bayer as it works to limit financial exposure from tens of thousands of remaining claims. Achieving a defense verdict after the Supreme Court ruling strengthens the company's position as its broader settlement package moves through the legal review process. A Missouri judge is reviewing the proposed $7.25 billion settlement to decide whether to grant formal approval. This article is intended for informational purposes only. It does not constitute investment advice.